---
title: Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy
  in older patients ineligible for chemotherapy
date: '2023-11-10'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37946283/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20231111170732&v=2.17.9.post6+86293ac
source: Blood
description: Older patients with advanced-stage classical Hodgkin lymphoma (cHL) have
  inferior outcomes compared with younger patients, potentially due to comorbidities
  and frailty. This noncomparative phase 2 study enrolled patients ≥60 years with
  cHL unfit for conventional chemotherapy to receive frontline brentuximab vedotin
  (BV; 1.8 mg/kg) with dacarbazine (DTIC; 375 mg/m2) (Part B) or nivolumab (Part D;
  3 mg/kg). In Parts B and D, 50% and 38% of patients, respectively, had ≥3 general
  comorbidities or ...
disable_comments: true
---
Older patients with advanced-stage classical Hodgkin lymphoma (cHL) have inferior outcomes compared with younger patients, potentially due to comorbidities and frailty. This noncomparative phase 2 study enrolled patients ≥60 years with cHL unfit for conventional chemotherapy to receive frontline brentuximab vedotin (BV; 1.8 mg/kg) with dacarbazine (DTIC; 375 mg/m2) (Part B) or nivolumab (Part D; 3 mg/kg). In Parts B and D, 50% and 38% of patients, respectively, had ≥3 general comorbidities or ...